There is some really good news for those of us who live in areas where The National Institute for Health and Care Excellence (NICE) recommends drug approvals.  NICE has issued a final draft guidance recommending that men with hormone-relapsed prostate cancer (castrate resistant) that has metastasized and has been treated with docetaxel (chemotherapy) should be given access to Xtandi (enzalutamide), even if they had prior exposure to Zytiga (abiraterone).  The prior recommendation did not permit men with prior Zytiga exposure to receive Xtandi.

NICE changed their original guidance, men who had prior Zytiga exposure would not benefit from Xtandi after Astellas provided observations showing that Xtandi worked in a portion of men who had received previous treatment with Zytiga.

Commenting o